

RNS Number : 3584U
Ananda Developments PLC
28 March 2023

ANANDA DEVELOPMENTS PLC

("Ananda" or the "Company")

Ananda is an AQSE-listed medical cannabis company creating UK-based operations to grow and provide carbon zero, consistent, medical cannabis for the UK and international markets.

Medical Cannabis Research Roundup

Issue eighteen

Summary:

In the last month there was an interesting mix of papers showing the efficacy and explaining the mechanisms of action of cannabis in a variety of indications. This included diabetes, Alzheimer's and bladder pain syndrome, as summarised below.

10:1 CBD:THC sublingual spray shows promising results in Diabetes Type 2 patients

In vitro study helps to explain mechanisms of action of CBD alleviating bladder pain syndrome

Medical cannabis use to improve functioning of Alzheimer's patients

10:1 CBD:THC sublingual spray shows promising results in Diabetes Type 2 Patients

The study investigated the efficacy and safety of a sublingual spray - comprising a combination of CBD and Δ 9-THC in a 10:1 ratio (delivering 200 mg/20 mg CBD/ Δ 9-THC), administered two puffs each time, twice per day over an eight-week treatment period - on glycemic state and lipid profiles of patients with type II DM.

A statistically significant decline in total cholesterol, triglyceride, LDL-C, FBS, Hb A1C and insulin secretion was observable in the patients treated at the end of the 8-week treatment period.

Regarding safety, the mentioned adjunctive regimen was well tolerated, and there were no serious or severe adverse effects. This study demonstrated that the sublingual spray could be a new therapeutic agent for lipid and glycemic control in diabetic patients.

Reference:

A Phase I Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety Profile of a Sublingually Administered Cannabidiol /Delta 9-tetrahydrocannabidiol (10: 1) Regimen in Diabetes Type 2 Patients

<https://brieflands.com/articles/ijpr-132647.html>



***In vitro* study helps to explain mechanisms of action of CBD alleviating bladder pain syndrome**

Interstitial Cystitis (IC) or Bladder Pain Syndrome (BPS) is a chronic inflammatory disease of the urinary bladder of unknown cause. IC/BPS is associated with depression and lower quality of life. Many of those affected also have irritable bowel syndrome and fibromyalgia.

This condition is often confusable and comorbid with other pelvic pain disorders and involves the bladder mucosa, peripheral inflammation. Treatment for the disease remains suboptimal.

Several animal studies have described the potential effect of cannabidiol (CBD) in alleviating the symptoms of IC/BPS.

This study investigated the effect of CBD against inflammation and oxidative stress in an *in vitro* model of IC/BPS comprised of TNF α -stimulated human urothelial cells SV-HUC1.

Results show that CBD treatment of urothelial cells significantly decreased TNF α -upregulated mRNA and protein expression of IL1 α , IL8, CXCL1, and CXCL10, as well as attenuated NF κ B phosphorylation. In addition, CBD treatment also diminished TNF α -driven cellular reactive oxygen species generation (ROS).

Observations provide new insights into the therapeutic potential of CBD through modulation of PPAR γ /Nrf2/NF κ B signalling pathways, which could be further exploited in the treatment of IC/BPS.

Reference:

Cannabidiol as a Promising Therapeutic Option in IC/BPS: In Vitro Evaluation of Its Protective Effects against Inflammation and Oxidative Stress

<https://www.mdpi.com/1422-0067/24/5/5055>

Medical Cannabis Use Found to Improve Functioning of Alzheimer's Patients

There are 10 million new cases of dementia reported each year worldwide. The most common symptoms of dementia are agitation and weight loss. As new treatments are being explored, medical cannabis use is increasing in patients with Alzheimer's.

A retrospective trial looked at enhancing the clinical use of a cannabis extract for Alzheimer's patients. 30 Alzheimer's patients, aged 65-90 years old, were treated with a cannabis extract diluted in olive oil, containing 22% THC and 0.5% CBD, twice daily. Patient data was then collected from questionnaire responses over the 12-week study.

45% of patients who were treated with MCBP improved in mental functioning. The data showed the cannabis extract reduced agitation, sleep and eating issues whilst improving caregiver stress. All patients were less physically and verbally aggressive.

Larger patient studies, with a control and self-reported data, are needed to better understand the effects of cannabis extracts on Alzheimer's patients.

Reference:

Oral THC: CBD cannabis extract in main symptoms of Alzheimer's disease: agitation and weight loss

<https://pubmed.ncbi.nlm.nih.gov/36655645/>



-Ends-

The Directors of the Company accept responsibility for the contents of this announcement.

ANANDA DEVELOPMENTS PLC +44 (0)7463 686 497

Chief Executive Officer

Melissa Sturgess

Investor Relations

Jeremy Sturgess-Smith

PETERHOUSE CAPITAL LIMITED +44 (0)20 7469 0930

Corporate Finance

Mark Anwyl

Corporate Broking

Lucy Williams

Duncan Vasey

About Ananda Developments

Ananda is an AQSE-listed medical cannabis company creating UK-based operations to grow and provide carbon zero, consistent, medical cannabis for the UK and international markets.

For more information, please visit: <https://anandadevelopments.com/>

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).